LifeCare-backed Kuros raises CHF 5m extension

Undisclosed new investors provided the capital. The funding will be an addition to the CHF 15m that Kuros raised in August this year, bringing the round to CHF 20m in total.

The company stated that the additional funding will help to accelerate the product's market launch and to enable the final stage of clinical testing.

According to unquote" data, activity in the Swiss biotech sector has hit a lull this year. While 2013 saw a solid number of 10 early-stage and expansion deals, dealflow fell slightly in 2014 and only five capital injections were recorded for 2015 so far.

Previous funding
Swiss VC LifeCare Partners and Dutch VC Life Sciences Partners led Kuros's financing round in August this year, with participation from VI Partners, Venture Incubator, the Swiss Helvetia Fund and family offices from Germany and Switzerland. Omega Funds, a US-based life sciences-focused fund, also became a shareholder during the last financing round.

Company
Headquartered in Zurich, Kuros develops biomaterials used for wound healing, tissue sealant and orthobiologics. The company was founded in 2000 in a spin-off from the Swiss Federal Institute of Technology and University of Zurich.

People
Didier Cowling is CEO of Kuros.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• DACH
• Healthcare
• Early-stage
• Switzerland
• Life Science Partners